A detailed history of Bank Of America Corp transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Bank Of America Corp holds 130,825 shares of COLL stock, worth $4.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
130,825
Previous 198,498 34.09%
Holding current value
$4.51 Million
Previous $7.71 Million 45.33%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$31.36 - $39.99 $2.12 Million - $2.71 Million
-67,673 Reduced 34.09%
130,825 $4.21 Million
Q1 2024

May 15, 2024

BUY
$31.23 - $40.91 $5.62 Million - $7.36 Million
179,952 Added 970.3%
198,498 $7.71 Million
Q4 2023

Feb 14, 2024

SELL
$21.16 - $30.8 $286,591 - $417,155
-13,544 Reduced 42.21%
18,546 $570,000
Q2 2023

Aug 14, 2023

BUY
$21.06 - $24.0 $112,734 - $128,472
5,353 Added 20.02%
32,090 $689,000
Q1 2023

May 12, 2023

SELL
$23.0 - $29.88 $156,768 - $203,662
-6,816 Reduced 20.31%
26,737 $641,000
Q4 2022

Feb 10, 2023

BUY
$16.14 - $23.55 $260,531 - $380,144
16,142 Added 92.71%
33,553 $778,000
Q3 2022

Nov 14, 2022

SELL
$15.46 - $20.1 $205,045 - $266,586
-13,263 Reduced 43.24%
17,411 $279,000
Q2 2022

Aug 12, 2022

SELL
$14.22 - $20.88 $384,693 - $564,866
-27,053 Reduced 46.86%
30,674 $543,000
Q1 2022

May 16, 2022

BUY
$17.2 - $22.5 $574,566 - $751,612
33,405 Added 137.34%
57,727 $1.18 Million
Q4 2021

Feb 08, 2022

BUY
$17.5 - $21.35 $11,917 - $14,539
681 Added 2.88%
24,322 $454,000
Q3 2021

Nov 15, 2021

SELL
$17.75 - $25.39 $249,760 - $357,262
-14,071 Reduced 37.31%
23,641 $468,000
Q2 2021

Sep 13, 2021

BUY
$21.74 - $25.28 $819,858 - $953,359
37,712 New
37,712 $891,000

Others Institutions Holding COLL

About COLLEGIUM PHARMACEUTICAL, INC


  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.18B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.